Searching across hundreds of databases
BRAF(V600E) mutant melanomas treated with inhibitors of the BRAF and MEK kinases almost invariably develop resistance that is frequently caused by reactivation of the mitogen activated protein kinase (MAPK) pathway. To identify novel treatment options for such patients, we searched for acquired vulnerabilities of MAPK inhibitor-resistant melanomas. We find that resistance to BRAF+MEK inhibitors is associated with increased levels of reactive oxygen species (ROS). Subsequent treatment with the histone deacetylase inhibitor vorinostat suppresses SLC7A11, leading to a lethal increase in the already-elevated levels of ROS in drug-resistant cells. This causes selective apoptotic death of only the drug-resistant tumor cells. Consistently, treatment of BRAF inhibitor-resistant melanoma with vorinostat in mice results in dramatic tumor regression. In a study in patients with advanced BRAF+MEK inhibitor-resistant melanoma, we find that vorinostat can selectively ablate drug-resistant tumor cells, providing clinical proof of concept for the novel therapy identified here.
Pubmed ID: 29754815 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This monoclonal targets Histone H2A.X pSer139
View all literature mentionsThis monoclonal targets RSK1 (D6D5) Rabbit mAb
View all literature mentionsThis monoclonal targets phospho-Rsk1 (Thr359/Ser363) rabbit monoclonal
View all literature mentionsThis monoclonal targets Cleaved PARP (Asp214)
View all literature mentionsThis monoclonal targets Raf-B (F-7)
View all literature mentionsThis polyclonal targets Phospho-B-Raf (Ser445)
View all literature mentionsThis monoclonal targets PDGF Receptor β
View all literature mentionsThis monoclonal targets Pan Ras
View all literature mentionsThis monoclonal targets SHP2 (phospho Y542)
View all literature mentionsThis polyclonal targets PTPN11
View all literature mentionsThis monoclonal targets MEK1 / MEK2
View all literature mentionsThis monoclonal targets Phospho-MEK1/2 (Ser217/221)
View all literature mentionsThis polyclonal targets Phospho-Rb (Ser780)
View all literature mentionsThis polyclonal targets Histone H3
View all literature mentionsThis monoclonal targets ACTG1, ACTC1, ACTA1, ACTA2, ACTG2, ACTB
View all literature mentionsThis monoclonal targets alpha-Tubulin
View all literature mentionsThis monoclonal targets Vinculin antibody produced in mouse
View all literature mentionsThis polyclonal targets HSP90AA1, HSP90AB1, HSP90B1
View all literature mentionsCell line 888-mel is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsCell line COLO 741 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsCell line SK-MEL-147 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsCell line SK-MEL-2 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsCell line A-375 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsThe SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
